Embecta (EMBC) Cash from Financing Activities (2020 - 2026)
Embecta (EMBC) reported Cash from Financing Activities of -$41.5 million for Q1 2026, down 11.26% on a YoY basis from -$46.8 million in Q1 2025, and up 19.57% sequentially from -$51.6 million in Q4 2025.
Embecta (EMBC) Cash from Financing Activities (2020 - 2026) Analysis & Trends
Embecta (EMBC) has 7 years of Cash from Financing Activities data on file, last reported at -$41.5 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Financing Activities fell 11.26% year-over-year to -$41.5 million; the trailing twelve-month figure through Mar 2026 stood at -$237.3 million (down 81.7% YoY), and the FY2025 full-year result was -$226.7 million, down 208.86% from the prior year.
- Cash from Financing Activities grew to -$41.5 million in Q1 2026, from -$51.6 million in the prior quarter.
- In the past five years, Cash from Financing Activities ranged from a high of $90.3 million in Q1 2022 to a low of -$81.6 million in Q3 2025.
- A 5-year average of -$20.9 million and a median of -$13.5 million in 2023 frame the typical range for Cash from Financing Activities.
- Across the five-year window, Cash from Financing Activities soared 179.63% in 2022 and slumped 469.7% in 2023, its largest moves.
- Tracing EMBC's Cash from Financing Activities over 5 years: stood at -$6.1 million in 2022, then sank by 121.31% to -$13.5 million in 2023, then tumbled by 234.81% to -$45.2 million in 2024, then slipped by 14.16% to -$51.6 million in 2025, then advanced by 19.57% to -$41.5 million in 2026.
- Business Quant data shows EMBC's Cash from Financing Activities at -$41.5 million in Q1 2026, -$51.6 million in Q4 2025, and -$81.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alcon | 32,734,969.19 Bn | 32,734,967.53 Bn | 1.53 Bn | -133.00 Mn |
| 2 | Intuitive Surgical | 117.50 Bn | 112.41 Bn | 1.96 Bn | -287.90 Mn |
| 3 | Becton Dickinson | 42.93 Bn | 42.11 Bn | 2.15 Bn | -414.00 Mn |
| 4 | Medline | 30.82 Bn | 36.66 Bn | 1.84 Bn | -13.00 Mn |
| 5 | Resmed | 27.90 Bn | 26.23 Bn | 890.98 Mn | -255.24 Mn |
| 6 | West Pharmaceutical Services | 26.76 Bn | 26.23 Bn | 329.20 Mn | -164.80 Mn |
| 7 | Cooper Companies | 15.30 Bn | 15.16 Bn | 735.40 Mn | -75.80 Mn |
| 8 | Solventum | 13.46 Bn | 12.90 Bn | 1.10 Bn | -50.00 Mn |
| 9 | Align Technology | 12.02 Bn | 10.96 Bn | 736.59 Mn | -48.13 Mn |
| 10 | Embecta | 192.72 Mn | -678,250.00 | 127.80 Mn | -41.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -41.50 Mn |
| Mar 31, 2026 | -41.50 Mn |
| Dec 31, 2025 | -51.60 Mn |
| Dec 31, 2025 | -51.60 Mn |
| Sep 30, 2025 | -81.60 Mn |
| Sep 30, 2025 | -81.60 Mn |
| Jun 30, 2025 | -62.60 Mn |
| Jun 30, 2025 | -62.60 Mn |
| Mar 31, 2025 | -37.30 Mn |
| Mar 31, 2025 | -37.30 Mn |
| Dec 31, 2024 | -45.20 Mn |
| Dec 31, 2024 | -45.20 Mn |
| Sep 30, 2024 | -36.60 Mn |
| Sep 30, 2024 | -36.60 Mn |
| Jun 30, 2024 | -11.50 Mn |
| Jun 30, 2024 | -11.50 Mn |
| Mar 31, 2024 | -11.80 Mn |
| Mar 31, 2024 | -11.80 Mn |
| Dec 31, 2023 | -13.50 Mn |
| Dec 31, 2023 | -13.50 Mn |